AlloSeq cfDNA
Solid-organ Transplant Surveillance
AlloSeq cfDNA is an innovative NGS solution that provides a risk assessment of allograft rejection by measuring dd-cfDNA. Cell-free DNA is a clinically validated biomarker to measure the small amount of dd-cfDNA from plasma. AlloSeq cfDNA analyses transplant specific SNPs across the genome without prior genotyping.
To Request a Demo
AlloSeq cfDNA
- Targets 202 bi-allelic SNPs across 22 autosomes
- Test up to 24 samples/run
- Validated on Illumina MiniSeq and MiSeq
- No prior genotyping required
- Analytically validated by multi-centric study
- From cfDNA sample to reported result < 24 hrs with < 1.5 hrs hands-on time
- Allows reporting dd-cfDNA as fraction
- Ability to calculate absolute copies
- Ability to monitor more than one donor cfDNA contributor
For Full Details Visit
Ordering Details
